Lakewood-Amedex Biotherapeutics Inc. Common Stock LABT · Stock Open Lakewood-Amedex Biotherapeutics Inc. Common Stock in new tab
Lakewood-Amedex Biotherapeutics Inc. Common Stock Analysis (LABT)
Is Lakewood-Amedex Biotherapeutics Inc. Common Stock a good investment? Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) is currently trading at 2.16 USD.
Earnings Schedule: Lakewood-Amedex Biotherapeutics Inc. Common Stock is expected to release its next earnings report on Aug. 28, 2026.
Investor FAQ
Does Lakewood-Amedex Biotherapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Lakewood-Amedex Biotherapeutics Inc. Common Stock?
Lakewood-Amedex Biotherapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 28, 2026. The company currently has a trailing EPS of -3.26.
Company Profile
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
| Split Date | Split Ratio to 1 |
|---|---|
| June 22, 2026 | 0.100000 |
Community Discussion